Alnylam Pharmace. buy Truist Financial Co.
Start price
21.07.25
/
50%
€275.00
Target price
21.07.26
€331.29
Performance (%)
3.24%
Price
01.04.26
€283.90
Summary
This prediction is currently active. With a performance of 3.24%, the BUY prediction by Truist_Financial_Co_ for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 21.07.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -0.176% | -0.176% |
| iShares Core DAX® | 2,49 % | -5,94 % |
| iShares Nasdaq 100 | 1,65 % | -2,46 % |
| iShares Nikkei 225® | 0,55 % | -7,60 % |
| iShares S&P 500 | 1,35 % | -2,94 % |
Comments by Truist_Financial_Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $385.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€343.00
08.01.26
08.01.26
€454.00
08.01.27
08.01.27
-17.23%
01.04.26
01.04.26
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€418.20
17.10.25
17.10.25
€457.16
17.10.26
17.10.26
-32.11%
01.04.26
01.04.26